A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

✍ Scribed by Li, D.; Pant, S.; Ryan, D.P.; Laheru, D.; Bahary, N.; Dragovich, T.; Hosein, P.J.; Rolfe, L.; Saif, M.W.; LaValle, J.; Yu, K.H.; Lowery, M.A.; Allen, A.; O'Reilly, E.M.

• Book ID: 126551169
• Publisher: S. Karger AG
• Year: 2014
• Tongue: English
• Weight: 222 KB
• Volume: 14
• Category: Article
• ISSN: 1424-3903
• DOI: 10.1016/j.pan.2014.07.003